Dupixent® considerably cut down on COPD flare-ups in its subsequent effective Phase 3 investigation, hastening its FDA application and affirming its potential as the initial sanctioned biologic treatment for this severe illness.
On Dec 11, 2023, new clinical data on zilurgisertib (INCB000928, LIMBER-104), alone or with ruxolitinib for myelofibrosis-related anemia, will be presented at ASH 2023.
Innovent makes announcement: China's National Medical Products Administration has permitted and given precedence in reviewing the new drug application, IBI351 - the first KRAS G12C inhibitor from the country.
A precursor in biology refers to a substance, cell, or cellular component that serves as a predecessor or antecedent for another substance, cell, or cellular component.
Acrotech Biopharma and Evive Biotech have successfully received FDA authorization to use Ryzneuta® (Efbemalenograstim alfa injection) for treating Neutropenia caused by Chemotherapy (CIN).
EirGenix Inc. has delivered news regarding the receipt of a marketing endorsement from the European Commission for their trastuzumab biosimilar medication (EG12014).
Batch sequence searches are even quicker with new batch search reports and ability to save all patent results to your workspace in one click. Learn how Bio lets you search hundreds of sequences for FTO clearance in a matter of minutes!
Vertex Pharmaceuticals has announced that the European Commission has approved an expanded label for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor to treat cystic fibrosis in children aged 2 to 5 with at least one F508del mutation in the CFTR gene.